A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design.
The development of a safe, affordable and effective malaria vaccine to form part of control schemes in malaria endemic countries is a priority for researchers and public health officials. SPf66 is the first malaria vaccine to have shown partial protection against natural challenge in a phase III trial carried out in a hypoendemic area of Colombia. This paper describes the rationale and design of the first field trial of SPf66 outside South America, and the first to be conducted in an area of high perennial transmission.
Alonso
P L
PL
Epidemiology Research Unit, Fundacio per a la Recerca Biomedica, Barcelona, Spain.
Tanner
M
M
Smith
T
T
Hayes
R J
RJ
Schellenberg
J A
JA
Lopez
M C
MC
Bastos de Azevedo
I
I
Menendez
C
C
Lyimo
E
E
Weiss
N
N
D000328:Adult; D000818:Animals; D002675:Child, Preschool; D004992:Ethics, Medical; D006801:Humans; D007223:Infant; D017780:Malaria Vaccines / Q000009:adverse effects / Q000276:immunology; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D010963:Plasmodium falciparum / Q000276:immunology; D015800:Protozoan Proteins / Q000276:immunology*; D016052:Protozoan Vaccines; D011994:Recombinant Proteins; D012449:Safety; D013636:Tanzania; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic